-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Tazemetostat Hydrobromide in Metastatic Melanoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Tazemetostat Hydrobromide in Metastatic Melanoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Tazemetostat Hydrobromide in Metastatic Melanoma Drug Details: Tazemetostat hydrobromide (Tazverik) is...
-
Product Insights
Rectal Cancer – Drugs In Development, 2023
Global Markets Direct’s, ‘Rectal Cancer - Drugs In Development, 2023’, provides an overview of the Rectal Cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development for Rectal Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Atezolizumab in Colon Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Atezolizumab in Colon Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Atezolizumab in Colon Cancer Drug Details: Atezolizumab (Tecentriq) is an antineoplastic...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Atezolizumab in Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Atezolizumab in Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Drug Details: Atezolizumab (Tecentriq) is an...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TT-702 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TT-702 in Solid Tumor report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.TT-702 in Solid Tumor Drug Details:TT-702 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TT-816 in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TT-816 in Non-Small Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TT-816 in Non-Small Cell Lung Cancer Drug Details: TT-816 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TT-702 in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TT-702 in Metastatic Castration-Resistant Prostate Cancer (mCRPC) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.TT-702 in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Drug Details:TT-702 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TT-816 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TT-816 in Solid Tumor report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TT-816 in Solid Tumor Drug Details: TT-816 is under development for the...